1 |
Hardwick AB, Ambrosy AP. Natriuretic peptides as a surrogate endpoint in clinical trials - a riddle wrapped in an enigma. Eur J Heart Fail 2019;21:621-3. [PMID: 30919550 DOI: 10.1002/ejhf.1448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
2 |
Butler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S, O'Connor CM, Pieske B, Pieske-Kraigher E, Sabbah HN, Senni M, Voors AA, Udelson JE, Carr J, Gheorghiade M, Filippatos G. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail 2020;26:429-37. [PMID: 32068002 DOI: 10.1016/j.cardfail.2020.02.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
3 |
Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, Lewis EF, Abraham WT, Teerlink J, Walsh M, Heidenreich P, Bozkurt B, Starling RC, Solomon S, Felker GM, Butler J, Yancy C, Stevenson LW, O'Connor C, Unger E, Temple R, McMurray J. Endpoints in Heart Failure Drug Development: History and Future. JACC Heart Fail 2020;8:429-40. [PMID: 32278679 DOI: 10.1016/j.jchf.2019.12.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
4 |
Metra M. May 2019 at a glance: epidemiology, drug effects on biomarkers, adverse events with LVAD. Eur J Heart Fail 2019;21:541-2. [PMID: 31069909 DOI: 10.1002/ejhf.1262] [Reference Citation Analysis]
|